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Abstract
Background: Offering financial incentives is an effective intervention for improving adherence in patients taking
antipsychotic depot medication. We assessed whether patients’ motivation for treatment might be reduced after
receiving financial rewards.
Methods: This study was part of Money for Medication, a multicentre, open-label, randomised controlled trial, which
demonstrated the positive effects of financial incentives on antipsychotic depot compliance. Three mental healthcare
institutions in Dutch secondary psychiatric care services participated. Eligible patients were aged 18–65 years, had been
diagnosed with schizophrenia or another psychotic disorder, had been prescribed antipsychotic depot medication or
had an indication to start using depot medication, and were participating in outpatient treatment. For 12 months,
patients were randomly assigned either to treatment as usual (control group) or to treatment as usual plus a financial
reward for each depot of medication received (€30 per month if fully compliant; intervention group). They were
followed up for 6 months, during which time no monetary rewards were offered for taking antipsychotic medication.
To assess treatment motivation after 0, 12 and 18 months, interviews were conducted using a supplement to the
Health of the Nation Outcome Scales (HoNOS) and the Treatment Entry Questionnaire (TEQ).
Results: Patients were randomly assigned to the intervention (n = 84) or the control group (n = 85). After 12 months,
HoNOS motivation scores were available for 131 patients (78%). Ninety-one percent of the patients had no or mild
motivational problems for overall treatment; over time, there were no significant differences between the intervention
and control groups. TEQ data was available for a subgroup of patients (n = 61), and showed no significant differences
over time between the intervention and control groups for external motivation (β = 0.37 95% CI: -2.49 – 3.23, p = 0.799);
introjected motivation (β = − 2.39 95% CI: -6.22 – 1.44, p = 0.222); and identified motivation (β = − 0.91 95% CI: -4.42 – 2.61,
p= 0.613). After the 6-month follow-up period, results for the HoNOS and TEQ scores remained comparable.
Conclusions: Offering financial incentives for taking antipsychotic depot medication does not reduce patients’
motivation for treatment.
Trial registration: Netherlands Trial registration, number NTR2350.
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Background
Non-adherence to antipsychotic medication remains
a considerable problem in the treatment of patients
with psychotic disorders [1, 2]; it is associated with
poor clinical outcomes such as increased psychiatric
symptoms, hospital admissions, violent crimes and
suicide rates [3–5]. Randomised controlled studies
demonstrated that medication adherence improved
when financial incentives were offered [6, 7]. How-
ever, a systematic review by Deci and colleagues
(1999) found that people who received performance-
contingent rewards showed lower levels of intrinsic
motivation than people who received no rewards [8].
This can arise if incentives are perceived as control-
ling [9]. Furthermore, this negative relationship be-
tween external rewards and intrinsic motivation
seems to be present both during, and after incentives
are being offered [10]. Therefore, it is conceivable
that offering financial incentives reduces patients’
motivation, as they may stop their medication intake
when incentives are no longer offered. This could
negatively affect the long-term treatment, particularly
of patients with schizophrenia.
Motivation for treatment, however, is a multidimensional
concept. According to the Self-Determination Theory (SDT
[11]), motivation to engage in activities ranges from “activ-
ities that are completely initiated and controlled by external
social forces (such as financial incentives), to activities that
are fully self-determined.” Within this continuum, SDT de-
fines three types of motivation [12]. External motivation re-
fers to individuals who seek treatment or help due to social
pressure or in order to avoid punishment or achieve
external rewards (e.g., monetary rewards). Introjected
motivation states that internal or personal conflicts
(e.g., feelings of guilt, shame or anxiety) are the pri-
mary reason for remaining in treatment. Finally, iden-
tified motivation refers to individuals who personally
identify with the goals of therapy – who, rather than
being motivated by qualifying for rewards or avoiding
internal conflicts, seek treatment for themselves.
Here, we consider identified motivation as the most
self-determined form of motivation, and view this
subtype as intrinsic motivation [13].
The aim of this study was to explore, in the con-
text of Money for Medication (M4M), a randomised
controlled trial [6], whether offering patients finan-
cial incentives to take antipsychotic depot medica-
tion reduced their motivation for treatment.
Motivation was assessed during a 12-month inter-
vention and a 6-month follow-up period. We also
explored the role of clinical variables that have an
impact on treatment motivation, such as illness
insight [14], medication adherence and the side-
effects of antipsychotic medication.
Methods
Study design and patients
Between May 2010 and October 2014, a total of 169 pa-
tients participated in our M4M randomised controlled
trial; a detailed account of the study design has been
published in the main trial paper [6]. Patients were re-
cruited from three mental healthcare institutions in the
Netherlands: Dual Diagnosis Center Palier, Parnassia,
and BavoEuropoort. These organisations primarily treat
patients with psychotic disorders and other severe men-
tal illnesses (often with comorbid substance use). Eligible
patients were aged 18–65 years, had a psychotic disorder
classified by the DSM-IV, had been prescribed or had an
indication to start antipsychotic depot medication, were
participating in outpatient treatment, and had given
written informed consent. Patients were excluded if they
were unable to participate due to cognitive impairments
or had insufficient understanding of the Dutch language.
Before participating in this study, all patients provided
written informed consent. The study was approved by
the Dutch Medical Ethical Trial Committee of Erasmus
University Medical Center (registration number
NL31406.097.10), and was registered in the Netherlands
Trial Registration (NTR2350).
Procedure
Patients were selected from the caseloads of the partici-
pating treatment teams on the basis of the selection cri-
teria, and were informed about the study by their
clinicians. Patients who participated were interviewed at
baseline, and after 12 and 18 months. They received €20
remuneration for each completed interview. After the
baseline interview, they were randomly assigned to
12 months, either of treatment as usual, or of treatment
as usual plus financial incentives to take the anti-
psychotic depot medication. Randomisation was strati-
fied by treatment site and three potential prognostic
factors: sex, comorbid substance-use disorder (absent vs.
present), and compliance with antipsychotic medication
in the 4 months before baseline (< 50% vs. ≥50%). The
principal investigator had no influence on the enrolment
process. Patients, clinicians, interviewers, and research
assistants were masked to group allocation before, but
not after, assignment.
Treatment as usual and intervention
Patients were randomly assigned to the intervention
(n = 84) or the control group (n = 85). The control
group received treatment as usual (TAU), both during
the 12-month intervention period and during the 6-month
follow-up phase. This treatment was provided by commu-
nity mental health teams. During TAU, clinicians encour-
aged patients to take their antipsychotic depot medication
as prescribed. If necessary, crisis services were used, or
Noordraven et al. BMC Psychiatry  (2018) 18:144 Page 2 of 7
patients were admitted to hospital. All patients received
their depot medication at the outpatient clinic, where it
was administered by psychiatric nurses.
Patients in the intervention group received TAU, plus
a financial reward for every depot of antipsychotic medi-
cation they took during the 12-month intervention
period. The maximum reward was €30 per month. The
amount per taken depot varied according to the fre-
quency of the prescription, which ranged between one
and four times per month (i.e., between €7.50 and €30
per depot). After the intervention period, all patients en-
tered the 6-month follow-up period and received TAU
without financial incentives.
Outcomes
To assess patients’ overall motivation for treatment, we
used a supplement to the Dutch translation of the
Health of the Nation Outcome Scales (HoNOS) [15, 16].
During this structured interview, one item specifically
measured motivation (supplement B; “How motivated
are you for your current treatment?”), which was rated
on a 5-point scale ranging from 0 (no problems) to 4
(very severe problems). On the basis of the skewed re-
sponse distributions, treatment motivation scores were
dichotomised into “no or mild problems” (scores 0, 1
and 2) and “severe problems” (scores 3 and 4). During
the course of the study many patients were lost-to-
follow up, as they did not show up for appointments
with the interviewers. After 12 months, HoNOS motiv-
ation scores were available for 131 patients (78%: 66
intervention vs. 65 control); after 18 months, they were
available for 109 patients (64%: 60 intervention vs. 49
control).
We also assessed treatment motivation using the
Dutch version of the Treatment Entry Questionnaire
(TEQ) [12, 17, 18]. This questionnaire consists of 27
items and distinguishes three subtypes of motivation: (1)
external, (2) introjected, and (3) identified. External mo-
tivation included 12 items (e.g., “The reason I am in
treatment is because other people have pressured me to
be here”); introjected motivation included 6 items (e.g.,
“I plan to go through with treatment, because I will feel
ashamed of myself if I don’t”); and identified motivation
included 9 items (e.g., “I decided to follow treatment be-
cause it feels important to me to personally deal with my
problems”). Each item was rated on a scale from 1
(strongly disagree) to 7 (strongly agree). Subscale scores
were computed by summing the item scores, with higher
scores reflecting a higher level of external, introjected or
intrinsic motivation. The TEQ was added after about
half of the patients were already interviewed at baseline.
Therefore, the TEQ was administered to 85 patients at
baseline (42 intervention and 43 controls). After
12 months, TEQ scores were available for 61 patients
(72%: 27 intervention vs. 34 control); after 18 months,
they were available for 49 patients (58%: 21 intervention
vs. 28 control).
Motivation covariates
To explore factors influencing treatment motivation, we
analysed the effects of illness insight, side-effects, and
medication adherence. To measure patients’ level of ill-
ness insight at baseline, we used the Dutch version of
the Positive and Negative Syndrome Scale (PANSS) [19].
For item A12 of the PANSS (“Do you have a psychiatric
disorder or mental health problem?”) patients were
asked to elaborate their answers. Responses were scored
on a scale from 1 (illness insight present) to 7 (active de-
nial of having a psychiatric disorder). To monitor com-
mon side-effects associated with the use of antipsychotic
medication, we also used the 17-item Antipsychotic
Side-effect Checklist (ASC) [20]. Each item was rated as
“symptom present” or “symptom absent”, and the total
number of reported side-effects was calculated (range:
0–17). Finally, we measured medication adherence,
which was defined as the Medication Possession Ratio
(MPR; [21]), i.e., the number of depots of antipsychotic
medication received, divided by the total number of de-
pots of antipsychotic medication prescribed during the
12-month intervention and 6-month follow-up period.
Statistical analyses
HoNOS motivation scores were dichotomised into “no
or mild problems” or “severe problems” at baseline, and
after 12 and 18 months. Baseline differences, response
rates and motivation trajectories were analysed using
(multivariate) logistic and multinomial regression. Sensi-
tivity analyses were conducted using different cut-off
scores and trajectory classifications to explore the effect
of the dichotomization and combination of HoNOS
scores. For TEQ motivation scores, we used generalised
linear models with a gamma distribution and logit link
to analyse differences between treatment groups. Regres-
sion models were compared on the basis of the log-
likelihood ratio. In our adjusted models we entered
stratification variables as covariates. As the participating
mental healthcare teams were reorganised during the
study, treatment site was not included. In TEQ motiv-
ation models we added baseline values, illness insight,
medication side-effects and medication adherence as co-
factors. Extended reports on sensitivity analyses and
modelling results are available on request from the cor-
responding author. All statistical analyses were per-
formed using SPSS (version 21.0).
Results
Table 1 presents the sociodemographic and clinical
characteristics of all patients at baseline (n = 169).
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Trajectories of motivation (baseline – 12 months)
Four categories were distinguished: (1) patients with
mild or no problems at baseline and after 12 months (n =
106; 81%); (2) patients with severe motivational problems
at baseline, who showed an improved treatment motiv-
ation after 12 months (n = 13; 10%); (3) patients with se-
vere motivational problems at baseline, who did not
improve (n = 8; 6%); and (4) patients with mild or no
problems at baseline who showed severe motivational
problems after 12 months (n = 4; 3%). Patients with
HoNOS scores at baseline and after 12 months (n = 131)
were compared with patients who had only HoNOS base-
line scores (n = 35). Logistic regression analyses were per-
formed with patient status (i.e., being in the subgroup or
not) as dependent variable and with patient characteristics
as predictor variables (i.e., age, gender, substance-use dis-
order, medication adherence, ethnicity, income, and illness
insight). There were no significant differences between the
HoNOS subgroups (not reported here to save space).
Between trajectories there were no differences for the
intervention and control patients (β = − 0.412, 95% CI
-1.15-0.33, p = 0.274; reference category 1). Sensitivity
analysis yielded similar results.
Main effects on motivation subtypes
We compared patients with TEQ scores at baseline and
after 12 months (n = 61) with those who had only a TEQ
baseline measure (n = 24). This showed a significant dif-
ference for baseline medication adherence (β = 0.35, 95%
CI 0.01–0.06, p = 0.008). The TEQ subgroup (n = 61)
also showed a difference with the rest of the sample (n =
108) for baseline medication adherence (β = 0.03 95% CI:
0.02–0.05, p = 0.000) and substance use (β = 1.24 95%
CI: 0.48–1.99, p = 0.001).
Adjusted regression models consisted of the stratifica-
tion variables (i.e., condition, gender, substance use, and
baseline medication adherence), and baseline motivation.
After 12 months of offering financial incentives, we
found no effects of treatment condition on any type of
motivation assessed on the TEQ. There were no mean
score differences in external motivation between the
intervention group (19.4 [SD:7.0]) and control group
(20.4 [SD:6.4] (adjusted difference of 0.37 points (95% CI
-2.5–3.2, p = 0.799)). Similarly, the mean score difference
in introjected motivation was non-significant between
the intervention group (18.4 [SD:9.4]) and control group
(21.0 [SD:10.1] (adjusted difference of − 2.4 points (95% CI
-6.2–1.4, p = 0.222)). Finally, we found that the mean score
for identified motivation was not lower in the intervention
group (27.5 [SD:9.8]) than in the control group (27.9
[SD:9.4]) (adjusted difference of − 0,91 points (95% CI
-4.4–2.61; p = 0.613)).
Motivation covariates
To explore the association with motivation, we added
the following to the model: medication side-effects, ill-
ness insight (assessed at baseline), and medication ad-
herence (Table 2). Only illness insight had significant
main effects on introjected motivation (β = − 1,33 95%
CI: -2,47 – -0,19, p = 0,023) and identified motivation
Table 1 Patient characteristics and clinical status at baseline
Variable Total (n = 169) Intervention group (n = 84) Control group (n = 85)
Age mean (SD), years 40.7 (9.8) 40.6 (9.4) 40.7 (10.2)
Gender, N (%)
- Male 127 (75.1) 61 (72.6) 66 (77.6)
Patients > 50% medication adherence, N (%) 135 (79.9) 68 (80.0) 67 (79.8)
Place of treatment, N (%)
- The Hague 46 (27.2) 18 (21.4) 18 (21.2)
- Rotterdam 123 (72.8) 66 (78.6) 67 (78.8)
Substance use disorder, N (%) 94 (55.6) 48 (57.1) 46 (54.1)
Antipsychotic Medication side effects, mean (SD) 4,8 (4,0) 5,3 (4,0) 4,3 (3,9)
Illness insight; median (interquartile range) (range 1–7) 3 (1–4) 3 (1–4) 2 (1–4)
Health of the Nation Outcome Scales (HoNOS), N (%)
- No motivational problems 136 (80.4) 66 (78.6) 70 (82.3)
- Severe motivational problems 28 (16.6) 17 (20.2) 11 (12.9)
- Item missing 5 (3.0) 1 (1.2) 4 (4.8)
Treatment Entry Questionnaire, (TEQ) N (%) 85 (50.3) 42 (50.0) 43 (50.6)
- External motivation; mean (SD), (range 12–84) 18.4 (7.8) 17.6 (8.1) 19.0 (7.6)
- Introjected motivation; mean (SD), (range 6–42) 18.7 (10.6) 19.3 (9.4) 18.2 (9.4)
- Identified motivation; mean (SD), (range 9–63) 28.5 (10.0) 28.6 (10.9) 28.5 (9.2)
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(β = − 1,65 95% CI: -2,72 – -0,59, p = 0,002). This sug-
gests that less illness insight (reflected by higher
scores) is associated with less introjected motivation
for treatment, and less identified motivation for treat-
ment. There was no interaction effect of illness
insight and condition on either introjected motivation
(β = 0,49 95% CI: -1,80–2,78, p = 0,675) or identified
motivation (β = 0,63 95% CI: -1,43–2,69, p = 0,548).
Follow-up period (baseline – 18 months)
After the 6-month follow-up period, HoNOS motivation
supplement scores were available for 109 patients (64%).
These were divided into four categories: (1) patients who
continued (during 12–18 month follow-up) to have mild
or no motivational problems for treatment (n = 81; 75%);
(2) patients who had previously had severe motivational
problems (at baseline), but had now improved (n = 9;
8%); (3) patients who continued to have severe motiv-
ational problems throughout the study (from 0 to
18 months, n = 8; 7%); and (4) patients who had had
mild or no motivational problems before but had severe
problems at follow-up (n = 11; 10%). Per category, there
were no differences between the number of intervention
and control patients.
The adjusted model for 18-month TEQ scores showed
no significant differences between the intervention and
control groups for external motivation (β = 0.89 95%
CI: -4.68 – -2.89, p = 0.644), introjected motivation (β =
− 1.47 95% CI: -5.77 – -2.83, p = 0.449), and identified
motivation (β = − 2.15 95% CI: -6.14 – -1.84, p = 0.291).
There was a significant main effect for illness insight on
identified motivation (β = − 1.24 95% CI: -2.44 – -0.03,
p = 0.044), but no interaction effect of illness insight
and treatment condition.
Discussion
This study was intended to establish whether offering
patients financial incentives to take antipsychotic depot
medication would reduce their motivation for treatment.
Our findings suggest that it did not. Over time, patients
who received financial incentives did not differ with re-
spect to various types of motivation from those who re-
ceived treatment as usual. In addition, after the
discontinuation of financial incentives, their medication
adherence remained significantly higher.
After 12 months, 91% of the patients showed no or
only mild motivational problems. During the 6-month
follow-up period, when financial incentives were no lon-
ger offered, a majority of the patients (83%) were still
motivated for treatment, whereas relatively few (17%) re-
ported having little motivation for or resistance to their
current treatment. In sum, this study indicates that of-
fering and then discontinuing financial incentives to pa-
tients with psychotic disorders does not reduce their
motivation for clinical treatment. It is particularly note-
worthy that intrinsic motivation for treatment (which re-
fers to individuals who identify personally with the goals
of therapy) was not lower in patients who received fi-
nancial incentives than in control patients. Similarly, pa-
tients’ external motivation for treatment was not higher
after they had received financial incentives.
Strengths and limitations
This is the first study to assess the impact of financial in-
centives on patients’ motivation for treatment. Using
two questionnaires, HoNOS addendum and TEQ, to as-
sess treatment motivation, we found that offering finan-
cial incentives had produced no negative consequences.
The TEQ enabled us to measure motivationand also to
distinguish three subtypes of motivation.
However, the first limitation is that loss to follow-up
was considerable for the motivational outcome measures
in this study as patients often did not show up for
scheduled appointments with the interviewers. Organisa-
tional factors prevented us from administering the TEQ
to more than only a subgroup of patients and selection
Table 2 Coefficients for regression model, adjusted for medication side-effects, illness insight, or medication adherence
External motivation Introjected motivation Identified motivation
β 95% CI p value β 95% CI p value β 95% CI p value
Intercept 12.45 2.96; 21.94 0.011 5.71 −6.01; 17.41 0.341 7.41 −3.85; 18.67 0.197
Condition 0.37 −2.49; 3.23 0.799 − 2.39 −6.22; 1.44 0.222 −0.91 −4.42; 2.61 0.613
Gender 1.61 −1.82; 5.04 0.358 0.57 −4.09; 5.24 0.811 −3.76 −8.04; 0.52 0.085
Substance use 1.09 −1.88; 4.06 0.472 0.77 −3.26; 4.79 0.708 −0.28 −3.97; 3.42 0.884
Medication adherence baselinea −0.03 −0.11; 0.06 0.548 0.04 −0.07; 0.16 0.506 0.09 −0.02; 0.19 0.103
Motivation baselineb 0.43 0.25; 0.61 < 0.001 0.61 0.41; 0.81 < 0.001 0.56 0.39; 0.72 < 0.001
Medication side-effects −0.12 −0.54; 0.29 0.571 −0.11 −0.67; 0.46 0.714 0.34 −0.16; 0.84 0.181
Illness insight −0.29 −1.13; 0.54 0.486 −1.33 −2.47; − 0.19 0.023 −1.65 −2.72; − 0.59 0.002
Medication adherence 12 months −0.03 − 0.14; 0.07 0.542 − 0.02 −0.16; 0.12 0.796 0.02 −0.11; 0.15 0.711
a Medication adherence in the 4 months prior to baseline bMotivation measured at baseline for each type of motivation
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bias is likely to be an issue. The higher levels of medica-
tion adherence and fewer diagnoses of substance-use
disorder in this subgroup showed that they performed
somewhat better at the start of treatment than the rest
of the sample did. These patients may therefore have
been more motivated throughout the study: for example,
they may have had a high intrinsic motivation for treat-
ment. As there was a danger that financial incentives
would make them susceptible to adhering to treatment
more for the external rewards than for themselves, it is
important to note that there was no change in their in-
trinsic motivation when the financial incentives ended.
For other patient characteristics, this subgroup did not
differ significantly from the rest of the sample.
The second limitation is that overall treatment motivation
was assessed on the basis of one item from the HoNOS-
addendum scale, which thus reduced psychometric validity.
Another limitation is that, when the incentives ended, ex-
ternal motivation for treatment did not differ between the
intervention group and the control group. It might be ar-
gued that the financial incentives may not have been great
enough to cause major changes in patients’ external motiv-
ation for treatment. However, they were sufficient to
improve patients’ medication adherence during the inter-
vention period [6], and medication adherence remained sig-
nificantly higher for the intervention group when financial
incentives were no longer offered.
Further implications
Even though types of motivation did not differ between
the intervention and control groups, there was a signifi-
cant main effect for illness insight. Poor illness insight at
study entrance appears to have been associated with less
introjected and intrinsic motivation for treatment. These
effect sizes were rather small, however. Also, when the
intervention had finished, there seemed to be no so-
called “crowding out” effect [22]. In other words, not
only had patients not become externally motivated when
the incentives were removed, they had not lost their in-
trinsic motivation.
Conclusions
Financial incentives improve adherence to antipsychotic
depot medication in patients with psychotic disorders.
The current study suggests that offering such incentives
does not reduce patients’ motivation for clinical treatment.
It is particularly relevant that patients who received finan-
cial incentives had neither lower intrinsic motivation for
treatment nor higher external motivation. These results
remained similar during the follow-up period, when in-
centives were no longer offered. Financial incentives can
therefore be seen as an effective and relatively safe inter-
vention for improving depot-medication adherence among
patients with psychotic disorders.
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